Insider filing · HALO
Matthew L. Posard
Director
profile →
Halozyme Therapeutics, Inc.
HALO · Healthcare · 38 filings in 24 months
ticker →
Matthew L. Posard sold $2.0M of Halozyme Therapeutics (HALO)
Executed Sep 16, disclosed Sep 17, 1 day later.
Value, as filed
$2.0M
18,996 sh across 4 lots
Executed
Sep 16
the trade date, as filed
Disclosed
Sep 17
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MPMatthew L. Posard (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Halozyme Therapeutics, Inc. (HALO). The largest single filing was $2.0M of HALO (18,996 sh across 4 lots, as filed), executed Sep 16.
The name
HALOHealthcare · Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Matthew L. Posard in HALO
HALOSALE
Halozyme Therapeutics, Inc.
$478K4,400 sh across 2 lots
Exec Oct 1
Filed Oct 2 · 4:38 PM ET